Author Archives: collabrx

CollabRx Chief Medical Officer to Moderate Panel at Personalized Medicine World Conference (PMWC) 2016

Dr. George Lundberg and panelists to discuss Practicing Pathologists in Personalized Medicine SAN FRANCISCO, CA – December 10,  2015 – CollabRx, Inc. a leading clinical decision support company and wholly owned subsidiary of Rennova Health, Inc. (NASDAQ: RNVA) today announced that its Chief Medical Officer, George Lundberg, MD, will chair this year’s Personalized Medicine World Conference, Silicon Valley session titled, “The […]

Masthead

Molecular Disease Models & Applications Editors Editor-In-Chief George D. Lundberg, MD Executive Editor Smruti Vidwans, PhD Assistant Editors Michelle Turski, PhD Vivian Douglas, PhD Helen Sadik, PhD Editorial Advisory Board (Full List) George Lundberg, MD (Chair) Fred Appelbaum, MD Tanios (Tony) Bekaii-Saab, MD Douglas Blayney, MD Arthur Caplan, PhD Susan Cohn, MD E David Crawford MD […]

Cancer Specific Chief Editors

Melanoma Co-Chiefs David Fisher, MD Dr. Fisher is chief of the Massachusetts General Hospital Department of Dermatology at Harvard Medical School in Boston, Massachusetts (USA). He also serves as director of the MGH Cutaneous Biology Research Center and director of the Melanoma Center at MGH. Fisher’s research has focused on understanding the molecular and genetic […]

Editorial Advisory Board

George D. Lundberg, MD, Editor-In-Chief, Chair of the Editorial Advisory Board, & Chief Medical Officer In addition to serving as Editor-In-Chief for CollabRx, Dr. Lundberg is President and Chair of the Board of Directors of The Lundberg Institute, a Consulting Professor at Stanford University, and Editor at Large for Medscape from WebMD. Dr. Lundberg has […]

Products

Identify the most clinically relevant therapeutic options to inform treatment planning. The last several years have seen an explosion in the number of approved and investigational targeted cancer therapies. Confronted with an expanding landscape of molecularly-associated therapeutic options, oncologists need the right contextualized information to choose the best treatment options for specific patients. Find out […]

Health Commons: Therapy Development in a Networked World by Marty Tenenbaum and John Wilbanks

Drug Discovery: Time for a Change The pharmaceutical industry is at a crossroads. Despite revolutionary advances in molecular biology that have made genetic decoding routine, the time from gene to cure still stands at 17 years. High-throughput screening methods allow us to test the efficacy of millions of compounds against a molecular target in a […]

PLoS ONE: Targeted Therapy Database (and Analyzer)

Online Tools for Personalized Cancer Therapeutics Analysis We created a manually annotated database (Targeted Therapy Database, TTD) where the relevant data are gathered in a formal representation that can be computationally analyzed. Dedicated algorithms were set up for the identification of the prevalent therapeutic hypotheses based on the available evidence and for ranking treatments based […]

PLoS ONE: A Melanoma Molecular Disease Model

Peer Reviewed Molecular Disease Models While advanced melanoma remains one of the most challenging cancers, recent developments in our understanding of the molecular drivers of this disease have uncovered exciting opportunities to guide personalized therapeutic decisions. Genetic analyses of melanoma have uncovered several key molecular pathways that are involved in disease onset and progression, as well as prognosis. […]

CollabRx Scientists Jeff Shrager, Marty Tenenbaum, and Mike Travers Describe Cancer Commons in “Collaborative Computational Technologies for Biomedical Research”

Methods, Processes, and Tools for Collaboration “The time has come to fundamentally rethink how we handle the building of knowledge in biomedical sciences today. This book describes how the computational sciences have transformed into being a key knowledge broker, able to integrate and operate across divergent data types.”—Bryn Williams-Jones, Associate Research Fellow, Pfizer The pharmaceutical […]